IDH1 mutation decreases the invasiveness of glioma by downregulating the expression and activity of TAZ
Background and Aim: Gliomas carrying mutated isocitrate dehydrogenase 1 (IDH1) have an improved prognosis, but how this mutation improves survival is not known. In this study, we evaluated the correlation of expression of the gene transcriptional coactivator with PDZ-binding motif (TAZ) with IDH1 mu...
Main Authors: | Ningning Li, Rui Zhang, Yi Sun, Chenyue Xu, Yin Wang, Ji Xiong, Qi Chen, Ying Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Glioma |
Subjects: | |
Online Access: | http://www.jglioma.com/article.asp?issn=2589-6113;year=2019;volume=2;issue=1;spage=37;epage=45;aulast=Li |
Similar Items
-
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
by: Georgios Solomou, et al.
Published: (2023-05-01) -
Expression of IDH1, ATRX, p53 in Diagnosis of Gliomas as Per 2016 WHO Classification
by: Lokesh Kumar, et al.
Published: (2023-07-01) -
Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors
by: Santosh Sharma, et al.
Published: (2023-08-01) -
Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
by: Makoto Nakagawa, et al.
Published: (2022-06-01) -
Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications
by: Tianai Sun, et al.
Published: (2021-05-01)